top of page

NCI-2022-04663

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors


This Phase 1/2 study is looking at a drug called BLU-222 to see if it is safe and effective for treating advanced solid tumors. Researchers will test BLU-222 both on its own and in combination with other therapies. The main goals of the study are to understand how BLU-222 behaves in the body (pharmacokinetics), assess its safety, and determine if it can shrink tumors and improve patient outcomes

Phase 1/2: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2021-10597

A Phase 1 Open-Label, Dose-Escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients with Locally...

NCI-2022-10927

A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with...

NCT-05753722

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety,Pharmacokinetics, Pharmacodynamics, and Activity of...

Comments


bottom of page